following a full submission:
infliximab (Remicade®) is not recommended for use within NHS Scotland for maintenance treatment of severe, active Crohn's disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. Infliximab for the treatment of acute severe, active Crohn’s disease was approved by NICE in 2002.
Infliximab maintenance treatment, compared to placebo, is associated with higher rates of clinical remission and a longer time to loss of response in patients with active Crohn’s disease. The manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC.
Download detailed advice56KB (PDF)
Medicine details
- Medicine name:
- infliximab 100mg powder for intravenous infusion (Remicade)
- SMC ID:
- 363/07
- Indication:
- Severe, active Crohn's disease
- Pharmaceutical company
- Schering-Plough Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 07 May 2007